Avaco

Quick links to important sections

Avaco

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avaco

Property Description
Active ingredient Pravastatin sodium (Pravastatin Na)
Form Tablet (Oral solid preparation)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
General Purpose Foundational lipid management
Origin Semi-synthetic compound

What is Avaco and its Core Classification?

Avaco is the trade name for a single-ingredient medication containing Pravastatin sodium (Pravastatin Na) as its active substance. This medicine is classified as an HMG-CoA Reductase Inhibitor, placing it within the drug class commonly known as statins. The drug is typically available by prescription only (Rx) and is clinically recognized for its established role in lipid management.

The defining characteristic of Pravastatin is its mechanism of action, which involves selectively blocking the enzyme HMG-CoA reductase in the liver. This enzyme is the critical step in the liver's synthesis of cholesterol, meaning Avaco's primary function is to directly curtail the internal production of this lipid.

The Physical Form and Origin of Pravastatin

Avaco is supplied as an oral medication in the physical form of a tablet for patient consumption. The active substance, Pravastatin, is a semi-synthetic compound; it is chemically derived as a hydroxylated metabolite of the naturally occurring substance mevastatin. This chemical characteristic confirms its pharmaceutical origin as a modified natural product.

A distinctive feature of Pravastatin, compared to some other statins, is its hydrophilic (water-soluble) nature, which influences its primary metabolism within the liver. The tablet formulation utilizes standard solid pharmaceutical excipients to ensure stable delivery of the active ingredient through the oral route of administration.

What is Avaco's General Purpose?

The general purpose of Avaco is to serve as a foundational therapeutic tool for comprehensive lipid management in adults. By effectively reducing the internal synthesis of cholesterol, the medication works to correct an abnormal lipid profile, particularly by decreasing high levels of Low-Density Lipoprotein Cholesterol (LDL-C). Statins are recognized for their effectiveness in lowering LDL-C. This systemic action provides a primary benefit by supporting overall circulatory wellness, which is a recognized strategy for mitigating cardiovascular risks.

Regulatory References

  1. NIH Bookshelf Review

What side effects are possible with Avaco?

Possible Side Effects and Safety Information

The safety profile for Avaco, which contains the active substance Pravastatin, is derived exclusively from official regulatory documents and is structured by frequency and affected body system.

Adverse Reaction Classification

Side effects documented in regulatory labeling are classified by how often they occur:

  • Very Common (ge 1/10): This group includes musculoskeletal pain and upper respiratory tract infection.
  • Common (ge 1/100 to < 1/10): Adverse reactions frequently reported include myalgia (muscle pain), headache, nausea, diarrhea, and fatigue.
  • Uncommon (ge 1/1,000 to < 1/100): Less frequent events involve sleep disturbances (insomnia, nightmares), vertigo, visual disturbances, rash, and pruritus.

Serious Adverse Reactions and Safety Constraints

The official prescribing information identifies specific serious, albeit rare, risks. The most significant concern is the potential for Musculoskeletal Disorders, including Myopathy and Rhabdomyolysis, which is a severe muscle breakdown documented in the postmarketing experience. Hepatic Failure (fatal and non-fatal cases) has also been officially reported.

Safety constraints noted in regulatory documents include Contraindications for individuals with active liver disease or unexplained persistent elevations of serum transaminases, as well as those who are pregnant or breastfeeding.

Certain groups, such as older adults (age 65 years or greater) and individuals with renal impairment, are noted to have an increased risk for myopathy. The risk of muscle effects is also documented to be higher when the drug is used with certain interacting medications or when starting or increasing the dose.

Overdose and Emergency Response

Overdose Manifestations and Severity

Overdose events involving Avaco (Pravastatin sodium) are officially characterized by the potential for severe, life-threatening outcomes primarily affecting the musculoskeletal and renal systems. Documented presentations associated with high exposure include severe gastrointestinal symptoms such as abdominal pain, vomiting, and diarrhea. The most critical manifestation is the risk of Rhabdomyolysis, which is the breakdown of skeletal muscle tissue. This severe condition can subsequently lead to Acute Kidney Injury or Renal Failure. Post-marketing surveillance has also documented cases of fatal and non-fatal Hepatic Failure following exposure to the medicine.

Required Emergency Actions

Regulatory guidance mandates that immediate medical attention must be sought upon any confirmed or suspected overdose. Individuals experiencing unexplained muscle pain, tenderness, or weakness—especially if accompanied by dark urine—should contact emergency services or a national Poison Control Center immediately, as these are signs of potential severe toxicity.

Official Management Procedures

The management procedures documented by regulatory authorities are limited to symptomatic and supportive treatment. Discontinuation of Avaco therapy is required if severe muscle injury or hepatic damage is suspected. Ongoing monitoring involves mandatory assessment of Creatine Kinase (CK) levels for muscle involvement and hepatic transaminase levels (ALT, AST) to evaluate liver function. Regulatory documents note that the risk of severe musculoskeletal effects is higher in specific populations, including the elderly and individuals with renal impairment or uncontrolled hypothyroidism.

Therapeutic Uses of Avaco

Avaco (avacopan) is a medication applied across domains where additional symptomatic support is needed, particularly within the therapeutic area of immune-system diseases. This medicine is relevant for easing symptoms linked to a group of conditions characterized by periods of heightened symptoms known as anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This includes granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

The treatment is commonly used to help with symptom clusters that may become intense or disruptive, and is applied in addressing symptoms related to inflammatory or irritative states that are linked to the condition. It is applied when appropriate in clinical settings that involve acute or unstable symptom patterns, often alongside other supportive therapies. In scenarios marked by temporary physiological imbalance, the treatment contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases. Its use is intended to support the patient during difficult episodes by easing distress.


Quick Fact: Supportive Relief for Symptoms Related to Inflammatory States


Regulatory References

  1. Therapeutic Goods Administration (TGA) notice on avacopan

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Avaco

Eligibility Scope

The regulatory label defines who may use the medicine based on a strict set of required conditions and exclusions.

Classification Population or Condition
Allowed Use Adult patients (age ge 18) diagnosed with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA).
Contraindicated Patients with a serious hypersensitivity reaction to avacopan or any of its excipients.
Not Recommended Patients with severe hepatic impairment (Child-Pugh Class C) or active, untreated, and/or uncontrolled chronic liver disease (e.g., active Hepatitis B/C).
Avoid Use Patients with an active, serious infection, including localized infections.

Age and Physiological Restrictions

  • Age-Related Eligibility: Use is strictly for adults; safety and efficacy have not been established in children and adolescents under 18 years of age. No dose adjustment is required in older adults.
  • Pregnancy Status: The medicine is not recommended during pregnancy; women of childbearing potential should use effective contraception.
  • Renal Restrictions: Use has not been studied in patients with severe renal impairment (e.g., estimated glomerular filtration rate [eGFR] le 15 mL/min/1.73 m^2) or those who require dialysis.

Connection to the Overall Eligibility Profile

Regulatory documents define Avaco's eligibility by first limiting use to the specific adult patient population with GPA or MPA. They establish absolute exclusions (hypersensitivity) and conditional restrictions (hepatic failure, serious infection) as officially contraindicated or not recommended states. The medicine is also restricted as an adjunctive treatment that must be used in combination with standard background therapy.

What should I know about interactions with other medicines?

Avaco Interactions with other medicines and products

The regulatory profile for Avaco (Pravastatin sodium) details specific interactions that modify systemic drug exposure or create an additive risk for muscle-related adverse effects.

Interaction Classifications (High-Level)

Classification Example Interacting Substance Interaction Constraint
Avoided Combination Gemfibrozil Due to significant, officially documented increased risk of myopathy/rhabdomyolysis
Dose-Limited Combination Cyclosporine, Macrolide Antibiotics Potential for increased Avaco plasma exposure; requires maximum daily dose restriction
Timing-Dependent Interaction Bile Acid Sequestrants Reduces Avaco absorption; mandates specific dose separation
Additive Risk Interaction Niacin (high dose), Colchicine Increased risk of adverse skeletal muscle effects

Official Interaction Statements

  • The combination with Gemfibrozil is avoided based on the additive risk of skeletal muscle toxicity, as stated in prescribing information.
  • Co-administration with Cyclosporine causes a significant increase in Avaco exposure via transporter-mediated inhibition, requiring a regulatory maximum dose restriction.
  • Substances like Clarithromycin and Erythromycin also present a potential for increased Avaco exposure and necessitate a regulatory maximum dose restriction.
  • Bile Acid Sequestrants (e.g., Cholestyramine) reduce Avaco absorption, requiring Avaco to be administered at least 1 hour before or 4 hours after the sequestrant.
  • Heavy alcohol use is noted in regulatory caution, as it may increase the risk of liver damage.
  • The Elderly Population (Aged 65+) is documented to exhibit higher mean Avaco plasma exposure (AUC) compared to younger adults.

Mechanism of Action

Avaco (Pravastatin sodium) acts through a predominantly hepatoselective, two-pronged mechanistic approach primarily localized to the liver. This action initiates a cascade of molecular events that leads to both immediate metabolic changes and subsequent vascular modulation.


The Primary Mechanism: Competitive Inhibition of HMG-CoA Reductase

Avaco's principal action is its role as a competitive inhibitor of the enzyme HMG-CoA Reductase, the rate-limiting step in the Mevalonate pathway for cholesterol synthesis within liver cells. By restricting internal cholesterol production, this mechanism triggers a cellular feedback loop: liver cells upregulate the surface expression of LDL Receptors. This physiological adjustment enhances the liver’s capacity to actively capture and clear circulating LDL-C from the bloodstream, resulting in a sustained clearance of circulating LDL-C.


Secondary Pleiotropic Mechanism: Vascular and Endothelial Modulation

Beyond lipid clearance, the blockage of the Mevalonate pathway also restricts the downstream production of non-sterol intermediaries called isoprenoids. The resulting reduction in isoprenoids leads to the functional inhibition of small GTP-binding proteins (like RhoA) which regulate cellular signaling. This action relieves a natural inhibitory tone on the Endothelial Nitric Oxide Synthase (eNOS) enzyme. The subsequent increase in nitric oxide bioavailability modulates endothelial function and vascular tone. The anti-inflammatory effects engage pathways relevant to plaque stability.

Dosage and Administration Information

The administration of Avaco (avacopan) is based on specific clinical protocols to ensure consistent use in practice. The medicine is for oral administration and is supplied as a 10 mg hard capsule. The standard regimen for adults involves taking a dose of 30 mg twice daily (BID), which equals three 10 mg capsules per administration, resulting in a 60 mg total daily dosage.

The timing of Avaco intake is an essential component of its administration. The protocol involves taking each dose with food—once in the morning and once in the evening—to facilitate proper absorption. The hard capsules are to be swallowed whole with water and not crushed, chewed, or opened, which protects the delivery system of the active ingredient. The typical duration of the treatment course is established by clinical frameworks and is often described as a 52-week administration period.

For managing administration timing errors, the standard procedure for a missed dose is to skip it entirely, with the twice-daily schedule resuming at the next regularly scheduled time rather than doubling the dose. Dose modifications are documented for certain populations and co-administered drugs. For instance, no dose adjustment is described for older adults or patients with mild to moderate kidney or liver impairment. However, use is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). Furthermore, the dose is reduced to 30 mg once daily when the medicine is co-administered with strong CYP3A4 inhibitors.

Recent Clinical Evidence

Research evidence / Overview of studies for Avacopan

Evidence for Use in Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

The core research for Avacopan is derived from a large, global, controlled study that was evaluated in adults with active ANCA-associated vasculitis, specifically the types known as Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). This primary evidence was gathered from patients who were either newly diagnosed or experiencing a relapse of their condition. This research explored patterns that emerged when Avacopan was used alongside standard background treatments (either Rituximab or cyclophosphamide), with a comparator group receiving the standard approach which included a common steroid treatment called prednisone.

Researchers examined several outcomes related to disease control. The central goal was studied for disease remission, which meant reaching a very low level of disease activity without needing to take the study's assigned systemic steroids for treatment. The findings describe patterns observed in the studies regarding the achievement of initial and sustained disease remission at defined time intervals. The evidence contributes to the broader evidence landscape by providing context about how disease activity metrics changed in the study populations over the short and intermediate term.


The Role of Glucocorticoid Reduction in Trials

A key focus of the research was exploring study outcomes related to the overall amount of steroid medications required, known as glucocorticoids. The primary research examined and reported on the total cumulative dose of glucocorticoids that patients in each group received over the study period. This research reported changes measured during the study period related to the total cumulative amount of steroid medication received by patients.


What is Still Uncertain and Research Gaps

While the research provides context on how symptoms and disease activity metrics changed over the first year, the primary research evidence is limited as it is based on a single large-scale randomized trial, meaning independent confirmatory studies are not yet widely available. Certain secondary measures used in the trial to assess glucocorticoid-related effects may have limited validation in the context of the study, according to regulatory reviews. Furthermore, sample sizes were modest or data are still emerging for key subgroups, such as patients with very low kidney function (eGFR < 15 mL/min/1.73 m^2). The evidence helps describe short-term changes; however, long-term effects are not fully established in large, randomized cohorts.

Frequently Asked Questions (FAQ)

Common questions about Avaco (FAQ)


Q: Is Avaco the same type of medicine as [similar common drug name]?

Avaco is the trade name for pravastatin, which is part of the drug class called statins (HMG-CoA reductase inhibitors). All statins work by reducing cholesterol production in the liver. Official information indicates differences exist between statins, and this may be why official documents mention specific dose adjustments or contraindications when Avaco is used with certain interacting medicines.


Q: Does Avaco contain aspirin or ibuprofen?

The active ingredient in Avaco is Pravastatin sodium. According to official product labeling, Avaco is a single-ingredient formulation and does not contain aspirin, ibuprofen, or any other non-steroidal anti-inflammatory drugs (NSAIDs).


Q: How quickly does Avaco typically start working after it's been taken?

Regulatory pharmacokinetics data describes Avaco as being rapidly absorbed into the body, typically within 60 to 90 minutes of oral administration. The long-term cholesterol management patterns described in research are associated with consistent daily use over a longer time period.


Q: How long does the effect of a single dose of Avaco last in the body?

Pravastatin has a relatively short half-life, meaning the drug is eliminated from the bloodstream fairly quickly. Because of this short half-life, the regulatory instructions for use describe Avaco as a medicine intended for once-daily administration to support sustained management of cholesterol levels.


Q: Are there any specific foods or drinks to avoid while using Avaco?

Official documentation specifies that Avaco must be taken with food to help absorption, but it does not typically list any specific foods that must be avoided. However, regulatory caution notes that heavy alcohol use may increase the risk of liver problems when using the medicine, and is typically a matter for discussion with a health professional.


Q: Is Avaco known to interact with common over-the-counter allergy medications?

The official interaction profile for Avaco focuses mainly on strong inhibitors and certain prescription drugs like Gemfibrozil and Cyclosporine. The product label does not specifically list common over-the-counter allergy medications as a known interaction, but official advice suggests reviewing all medications, including OTCs and supplements, with a health professional.


Q: Are there any reported interactions between Avaco and vitamin or mineral supplements?

Regulatory documents state that using Avaco with high-dose Niacin (Vitamin B3) carries an increased risk of adverse muscle effects. There is not enough official information on the safety of all other complementary medicines, vitamins, or herbal remedies, and their combined use is typically a matter for discussion with a healthcare professional.


Q: Can people with high blood pressure safely use Avaco?

While official eligibility criteria do not list high blood pressure as a contraindication, the overall management of a patient's health status, including pre-existing conditions, is typically reviewed by a prescribing professional.


Q: Is Avaco associated with weight gain or weight loss?

The official adverse reaction list for Avaco, which details side effects reported in clinical studies, does not include weight gain or weight loss as a listed side effect classified by frequency. You can review the full list of possible side effects in the dedicated section.


Q: Can Avaco affect fertility or reproductive health?

Avaco is not recommended during pregnancy because cholesterol is vital for fetal development and the drug may cause harm. For this reason, official product information indicates that women of childbearing potential should use effective contraception to prevent pregnancy during use.


Q: How does Avaco affect the body's immune system?

Avaco's primary effect is on cholesterol synthesis. However, the mechanism of action also involves a secondary pathway that modulates the vascular lining and includes anti-inflammatory effects. These effects are generally considered relevant to overall circulatory health.


Q: Is Avaco a controlled substance or addictive?

Avaco (pravastatin) is classified as a prescription-only drug (Rx) but is not listed under the US Controlled Substances Act (CSA Schedule). This classification confirms that the drug is not considered to have an addiction or abuse potential under regulatory frameworks.


Q: What kind of monitoring is typically done when a person is using Avaco?

The FDA recommends that liver enzyme tests be done before starting Avaco, and then as clinically indicated if problems arise. Monitoring is also necessary if a patient reports unexplained muscle pain, tenderness, or weakness, as these may be signs of a serious muscle-related adverse reaction.


Q: Has Avaco been studied in children or adolescents?

Official regulatory documents indicate that Avaco is approved for use in children and adolescent patients ages 8 years and older with a condition called heterozygous familial hypercholesterolemia. However, its use in children younger than 8 years old has not been established.


Q: What should I know about Avaco's effect on the liver or kidneys?

Avaco is contraindicated if a patient has active liver disease or unexplained, persistent elevations in liver enzymes. Official information states that no dose adjustment is needed for mild-to-moderate kidney impairment, but its use has not been studied in severe kidney impairment.


Q: Are there specific instructions for stopping the use of Avaco?

Regulatory documents indicate that Avaco should be discontinued if serious side effects, such as a severe muscle disorder or severe liver injury, are suspected. Interrupting or stopping the medicine temporarily may also be recommended by a healthcare professional prior to major surgery or during an acute illness.


Q: Can Avaco be taken at the same time as antacids or heartburn medicine?

The official label specifies a required timing separation when taking Avaco with Bile Acid Sequestrants, which are used to treat high cholesterol. However, the label does not specifically address common over-the-counter antacids or heartburn medicines like proton pump inhibitors.


Q: Can Avaco affect mood or cause emotional changes?

Post-marketing safety reports have included rare, non-serious cases of temporary cognitive effects, such as confusion or memory loss. Official clinical trial data reported that the rate of issues like anxiety or nervousness was statistically similar between patients using pravastatin and those taking a placebo.


Q: Does Avaco interact with common vaccines, like the flu shot?

The official prescribing information for Avaco focuses on drug-drug interactions that affect how the medicine is processed in the body. The label does not list any known or reported interaction with common vaccines, such as the flu shot or other immunizations.


Q: Why do some people stop using Avaco?

Official documents indicate that discontinuing use is generally required due to the development of specific serious side effects. These include signs of potential liver injury or the onset of severe unexplained muscle problems.

How should Avaco be stored and disposed of?

Storage and Disposal Requirements

Avacopan (Tavneos) capsules must be stored according to defined regulatory conditions to ensure stability. Official labeling specifies storage at Controlled Room Temperature, which is between 20°C to 25°C (68°F to 77°F), allowing excursions up to 30°C (86°F).

The medication must be protected from light and kept from freezing. For safety and integrity, Avacopan must remain in the original bottle and be kept out of the reach and sight of children.

Disposal instructions state that any unused or expired product should be discarded in accordance with local requirements. Patients must consult a pharmacist or a local waste disposal company for guidance on appropriate handling and disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Avaco found in:

A-Z Index: